News

AB-Therapeutics hold the First Meeting of its international Scientific Advisory Board

June 1, 2011

AB-Therapeutics SL, a clinical-stage pharmaceutical biotech company in early 2012, held the first meeting of its International Scientific Advisory Board (SAB) in its facilities at Bellaterra, Barcelona on May 27th.



The meeting gathered together for the first time the whole panel of AB-Therapeutics advisors that is integrated by a group of experts that can support all aspects related to the research and development of cancer drugs, from discovery up to Phase II clinical trials. The SAB is composed by Antonio Perez MD (Chairman of the SAB) who held senior positions, including Medical Director,  in clinical development programs at Almirall, Novartis (Headquarters) and Esteve; Jesús Llenas PhD, former Head of Preclinical Pharmacology at Almirall; Peter Wyld MD, who held senior positions, including Medical Director, in clinical development of compounds for oncology at Novartis, J&J Oncologicals, Biogen and Amgen; José Miguel Lizcano PhD, who has strong expertise in signal transduction and is Professor at the Universitat Autònoma de Barcelona; José Luis Fábregas PhD, who was Senior Director of Pharmaceutical Development at Almirall; Jesús García Foncillas MD PhD, who have strong knowledge on clinical oncology and clinical development of new drug and is the is currently the Director of Oncology and Radiotherapy at the University Clinic, University of Navarra and is member of the Steering Committee for the European Medicines Agency (EMA); and José Luis Perez Gracia MD PhD, clinical oncologist at University Clinic, University of Navarra, with broad experience in drug development both at the academia and at the pharmaceutical company Eli Lilly.


The objectives of the meeting were fully achieved, and more specifically, evaluating the competitiveness of AB-Therapeutics technology, the identification of the strategy towards the successful Clinical Trial Application (CTA)  of the drug candidate ABTL0812 and the design of a  clinical trial envisaged to allow a proof of concept of this compound in cancer patients in early 2012.
The SAB agreed to meet again in a 6 month period to evaluate the evolution of the projects.

ABOUT AB-THERAPEUTICS

AB-Therapeutics is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a product ABT0812 in regulatory preclinical development, with Phase I clinical trials (first in man) starting early 2012. A second drug candidate ABT1014 will start preclinical development in 4Q2011.
Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
 
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits